Clearside Biomedical

Clearside Biomedical Equity Ratio

Delisted

The Equity Ratio of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -154.64 %. In the previous year, Equity Ratio was -46.78 % — a change of 230.60% (lower).

Equity Ratio

-154.64 %

YoY

230.60%

Last updated:

Equity Ratio of Clearside Biomedical is 2024 -154.64 % . Equity Ratio of Clearside Biomedical was 2023 -46.78 % . It decreases by 230.60% lower compared to the previous year.

The Clearside Biomedical Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2017
52.90 USD
Jan 1, 2018
53.54 USD
Jan 1, 2019
41.67 USD
Jan 1, 2020
45.34 USD
Jan 1, 2021
88.53 USD
Jan 1, 2022
20.68 USD
Jan 1, 2023
-46.78 USD
Jan 1, 2024
-154.64 USD
The Clearside Biomedical Equity Ratio history
YEAREquity RatioYoY
-154.64 %+230.60%
-46.78 %-326.16%
20.68 %-76.64%
88.53 %+95.25%
45.34 %+8.80%
41.67 %-22.16%
53.54 %+1.20%
52.90 %-37.39%
84.49 %+66.93%
50.62 %-31.58%
73.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Equity Ratio of Clearside Biomedical is -154.64 % in 2024.

Equity Ratio of Clearside Biomedical changed from -46.78 % to -154.64 %, representing a 230.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Clearside Biomedical

All Key Metrics — Clearside Biomedical